Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine

Aaron Diamond AIDS Research Center, New York, New York, United States of America.
PLoS ONE (Impact Factor: 3.23). 01/2010; 5(1):e8617. DOI: 10.1371/journal.pone.0008617
Source: PubMed


We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers.
ADVAX or placebo was administered intramuscularly at months 0, 1 and 3 to 45 healthy volunteers not at high risk for HIV-1. Three dosage levels [0.2 mg (low), 1.0 mg (mid), and 4.0 mg (high)] were tested. Twelve volunteers in each dosage group were assigned to receive ADVAX and three to receive placebo in a double-blind design. Subjects were followed for local and systemic reactogenicity, adverse events, and clinical laboratory parameters. Study follow up was 18 months. Humoral immunogenicity was evaluated by anti-gp120 binding ELISA. Cellular immunogenicity was assessed by a validated IFNgamma ELISpot assay and intracellular cytokine staining. ADVAX was safe and well-tolerated, with no vaccine-related serious adverse events. Local and systemic reactogenicity events were reported by 64% and 42% of vaccine recipients, respectively. The majority of events were mild. The IFNgamma ELISpot response rates to any HIV antigen were 0/9 (0%) in the placebo group, 3/12 (25%) in the low-dosage group, 4/12 (33%) in the mid-dosage group, and 2/12 (17%) in the high-dosage group. Overall, responses were generally transient and occurred to each gene product, although volunteers responded to single antigens only. Binding antibodies to gp120 were not detected in any volunteers, and HIV seroconversion did not occur.
ADVAX delivered intramuscularly is safe, well-tolerated, and elicits modest but transient cellular immune responses. NCT00249106.

Download full-text


Available from: Patricia Fast
  • Source
    • "ADVAX (Lot # 04030248, Vical, Inc., San Diego, CA), is a DNA vaccine based on pVAX1, a commercially available plasmid, containing consensus Chinese HIV-1 subtype C env gp160 and gag genes in one plasmid and pol and a nef/tat construct designed to express a fusion protein in the second plasmid mixed in a 1∶1 ratio [26], [27] and formulated in sterile isotonic salt solution containing 10 mM sodium phosphate and 150 mM sodium chloride. The 1 mL injection volume corresponded to 4 mg dosage level. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A randomized, double-blind, placebo controlled phase I trial. The trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of prime-boost vaccination regimens with either 2 doses of ADVAX, a DNA vaccine containing Chinese HIV-1 subtype C env gp160, gag, pol and nef/tat genes, as a prime and 2 doses of TBC-M4, a recombinant MVA encoding Indian HIV-1 subtype C env gp160, gag, RT, rev, tat, and nef genes, as a boost in Group A or 3 doses of TBC-M4 alone in Group B participants. Out of 16 participants in each group, 12 received vaccine candidates and 4 received placebos. Both vaccine regimens were found to be generally safe and well tolerated. The breadth of anti-HIV binding antibodies and the titres of anti-HIV neutralizing antibodies were significantly higher (p<0.05) in Group B volunteers at 14 days post last vaccination. Neutralizing antibodies were detected mainly against Tier-1 subtype B and C viruses. HIV-specific IFN-γ ELISPOT responses were directed mostly to Env and Gag proteins. Although the IFN-γ ELISPOT responses were infrequent after ADVAX vaccinations, the response rate was significantly higher in group A after 1(st) and 2(nd) MVA doses as compared to the responses in group B volunteers. However, the priming effect was short lasting leading to no difference in the frequency, breadth and magnitude of IFN-γELISPOT responses between the groups at 3, 6 and 9 months post-last vaccination. Although DNA priming resulted in enhancement of immune responses after 1(st) MVA boosting, the overall DNA prime MVA boost was not found to be immunologically superior to homologous MVA boosting. Clinical Trial Registry CTRI/2009/091/000051.
    Full-text · Article · Feb 2013 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: The performance evaluation model for CSMA/CD bus under heavy load is presented. Based on the definition of the critical point of heavy load and the description of difference between the average collision times of users and the system, a Markov transfer matrix of the system state is provided and the mathematical model which is suitable for evaluating the performance of CSMA/CD protocol under heavy load is established. After a comparison with the simulation results, an analytical approximation of the new method is presented and the results show that our model is close to the real system
    No preview · Conference Paper · Nov 1993
  • [Show abstract] [Hide abstract]
    ABSTRACT: The understanding of vacuum arc processes including the cathode and anode phenomena with cold and hot electrodes as well as the processes in interelectrode plasma is presented. In the case of cold electrodes, the current continuity mechanism, the nature of mass loss, spot motion, plasma jet generation in the spots and the cathode potential drop are reviewed. The explosive and gas-dynamical models of cathode spot operation are described. In the case of hot electrodes, the diffuse current continuity mechanism is analyzed. The present state of electrical and plasma characteristics of high current arcs in magnetic fields are discussed
    No preview · Conference Paper · Feb 2000
Show more